Across pharma and biotech teams, the conversation is shifting.
The challenge is no longer only how to respond once pressure becomes visible. It is how to build enough senior medical capacity into the model before review timelines start to slip, signatory responsibility becomes too concentrated or regional coverage becomes harder to sustain.
In many teams, the issue is not a lack of expertise. It is that the expertise exists in too narrow a bandwidth.
That is where delivery starts to feel fragile.
What is changing
Over recent months, we have seen a clearer pattern emerge across client conversations and active engagements.
Teams are becoming more deliberate about how they access senior medical expertise. Not only through permanent hires, but through interim, fractional and specialist support that can be introduced at the point where continuity matters most.
That shift is showing up in three places in particular.
1. Interim medical cover is becoming more strategic
Interim support used to be viewed mainly as a short-term solution.
Increasingly, it is being used more deliberately.
For many organisations, permanent headcount cannot move quickly enough to absorb sudden peaks in review demand, launch activity, congress preparation or programme expansion. Waiting until the pressure becomes obvious often means the delay is already under way.
The teams managing this well are using flexible senior medical support earlier, as a way to protect continuity rather than recover it.
2. Signatory pressure is harder to absorb
One of the clearest pressure points remains signatory and senior review capacity.
In theory, workflow may look manageable. In practice, the strain often sits with a very small number of people carrying responsibility for final medical judgement, approval and escalation.
That concentration creates risk quickly.
Review timelines become less predictable. Decisions take longer to land. Work begins queueing behind a handful of senior individuals whose capacity is already stretched.
In our experience, this is one of the areas where fractional or interim support can make the most immediate difference, particularly when demand rises faster than internal structures were built to handle.
3. Regional expertise is being added more flexibly
As programmes expand across Europe, APAC and beyond, medical delivery becomes more complex.
What looks manageable from a global planning perspective can become much harder to sustain at regional level when medical affairs, regulatory interpretation and local execution all need timely senior input.
We are seeing more teams look for flexible regional support rather than waiting for permanent structures to catch up.
That is especially true where timelines are moving quickly, local nuance matters and there is limited tolerance for delay.
Where we are seeing demand for senior medical cover most often
The practical need is usually showing up in familiar areas:
- Peak MLR review demand and final signatory cover
- Interim and fractional Medical Affairs support
- Medical monitoring reinforcement during active programme phases
- Regional medical input across Europe and APAC
- Flexible senior input around launch, submission and milestone pressure
These are not isolated issues. They are often connected.
When one part of the model becomes too dependent on a small number of senior people, the knock-on effect is felt across the wider programme.
What usually prompts teams to act
By the time support is being actively explored, the early signs are often already visible:
- Review timelines becoming less predictable
- Signatory work concentrating in too few people
- Regional medical input becoming harder to maintain
- Milestones putting visible strain on existing medical resource
- Teams becoming increasingly dependent on one or two senior decision-makers
Usually, none of these issues looks dramatic in isolation.
Together, they are a strong signal that continuity needs strengthening.
How MMD is responding
This April, My Medical Department marked 12 years of supporting pharmaceutical, biotech and life sciences teams with physician-led medical expertise.
Over that time, our role has remained consistent. We help clients access senior medical support when quality, continuity and timely decision-making matter most.
We have also recently strengthened our UK Medical Affairs capability with the appointment of Linnea Lindqvist-Brown, whose background includes AstraZeneca, Eisai, Roche and Pfizer, alongside ABPI Final Signatory experience.
That addition reflects something we are seeing clearly in the market. Clients increasingly need experienced support that can be deployed quickly, credibly and in a way that fits the realities of modern medical delivery.
A final thought
The most resilient teams are not always the ones with the largest structures.
They are often the ones that think earlier about continuity, senior decision-making capacity and how specialist expertise can be added without slowing everything else down.
That is where interim and fractional medical support is becoming more strategic.
And it is why more organisations are treating flexible senior medical cover not as a backup plan, but as part of how delivery is protected in the first place.
If your team is reviewing how to strengthen medical capacity without adding permanent headcount too quickly, we would be very happy to compare notes. Contact us at enquiries@mymedicaldepartment.com or visit www.mymedicaldepartment.com.
